Reinventing product and portfolio value for the biopharmaceutical industry

In this free issue of Delta magazine, the Medical, Consulting, Policy, Access, Value, and Evidence experts of Fishawack Health share their advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.

Download Delta magazine to:  

  • Learn about the insights that determine the evidence-generation plan, in turn improving clinical study design, generating focused patient insights, and providing the foundation for the real-world evidence strategy. 
  • Find out how manufacturers can build a holistic picture of each stakeholder upfront and create early alignment around the evidence gaps and benefits that will resonate with their target stakeholders. 
  • Discover why engaging early and regularly throughout product development can help mitigate challenges and avoid irreversible decisions being made without patient input that could impact the trajectory of the launch of your asset. 


FREE Ebook

Reinventing product and portfolio value for the biopharmaceutical industry

We respect your privacy. Cookie policy.

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...